Treatment of cancer by a combination of non-ionizing radiation and androgen deprivation

• US 20070155669A1
• Filed: 03/31/2006
• Published: 07/05/2007
• Est. Priority Date: 12/30/2005
• Status: Abandoned Application

• Current Assignee: Dornier MedTech Systems GmbH
• Original Assignee: Dornier MedTech Systems GmbH
• Inventors: Koshiba, Ken
• Application Number:
  US11/395,038
• Publication Number:
  US 20070155669A1
• Time in Patent Office: Days
• US Class Current: 514/10.100
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 38/09 Luteinising hormone-releasing hormone [LHRH] , i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
• CPC Class Codes: A61N 5/02 using microwaves
• CPC Class Codes: A61N 5/0601 Apparatus for use inside the body
• CPC Class Codes: A61N 7/00 Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092

Abstract

A combined androgen deprivation and thermotherapy cancer treatment. For example, the combination can be used to treat prostate cancer. Chemical compounds, including a non-steroidal anti-androgen and/or an LH-RH agonist, such as androgen deprivation therapy (“ADT”), can be used in combination with application of non-ionizing radiation to treat cancer. The chemical compounds can be administered before, simultaneously with, and/or after the application of the non-ionizing radiation. When the ADT is applied before the application of the radiation, a reduction in cancer volume can be expected. In patients treated in such a manner, evidence of recurring cancer was not observed.

Claims

1. A method for treating cancer, comprising the steps of:

applying non-ionizing radiation to a cancer patient; and

administering at least one of a non-steroidal anti-androgen, a luteinizing hormone (“

LH”

), a luteinizing hormone-releasing hormone (“

LH-RH”

), and an LH-RH agonist to the patient.

2. The method according to claim 1, wherein the anti-androgen comprises one of bicalutamide and flutamide.

3. The method according to claim 1, wherein the administering step comprises administering the non-steroidal anti-androgen using a dosage in a range of 10 mg/day to 1000 mg/day.

4. The method according to claim 1, wherein the agonist comprises one of leuprorelin acetate, goserelin acetate, buserelin acetate, and tripterelin.

5. The method according to claim 1, wherein the administering step comprises administering the agonist using a dosage in a range of 1 mg/4 weeks to 10 mg/4 weeks.

6. The method according to claim 1, wherein the patient has prostate cancer, and wherein the applying step comprises applying the radiation to the patient'"'"'s prostate gland.

7. The method according to claim 6, wherein the prostate cancer is an adenocarcinoma.

8. The method according to claim 1, wherein the administering step comprises orally administering the anti-androgen and subcutaneously administering the agonist.

9. The method according to claim 1, wherein the applying step occurs at least four weeks after the administering step.

10. The method according to claim 1, wherein the applying step occurs at least three months after the administering step.

11. The method according to claim 1, wherein the applying step occurs simultaneously with the administering step.

12. The method according to claim 1, wherein the applying step occurs before the administering step.

13. The method according to claim 1, wherein the applying step occurs after the administering step.

14. The method according to claim 1, wherein the administering step continues after the applying step for a period of at least one month.

15. The method according to claim 1, wherein the administering step continues after the applying step for a period of at least three months.

16. The method according to claim 1, wherein the non-ionizing radiation comprises heat-generating radiation.

17. The method according to claim 16, wherein the heat-generating radiation comprises one of microwave, laser light, and ultrasound.

18. The method according to claim 16, wherein the heat-generating radiation comprises microwave energy with a frequency range between 800 MHz to 1500 MHz.

19. The method according to claim 18, wherein the frequency range of the microwave energy is between 800 MHz and 1300 MHz.

20. The method according to claim 18, wherein the frequency range of the microwave energy is between 800 MHz and 1000 MHz.

21. The method according to claim 1, wherein the applying step comprises applying microwave radiation in a power range of 25 to 100 Watts to target tissue of the patient.

22. The method according to claim 21, wherein the power range of the microwave radiation is between 25 and 90 Watts.

23. The method according to claim 21, wherein the power range of the microwave radiation is between 25 and 85 Watts.

24. The method according to claim 1, wherein the applying step comprises applying microwave radiation by way of transurethral microwave thermoablation (TUMT).

25. The method according to claim 1, wherein the applying step comprises applying heat-generating microwave radiation for a period of between 10 minutes and 60 minutes.

26. The method according to claim 1, wherein the applying step comprises applying heat-generating radiation at a time of at least one month after a start of the administering step.

27. The method according to claim 1, wherein the applying step comprises applying heat-generating radiation at a time of at least three months after a start of the administering step.

28. The method according to claim 1, wherein the applying step comprises applying heat-generating radiation simultaneously with ongoing treatment of the administering step.

29. The method according to claim 1, wherein the applying step comprises applying heat-generating radiation in the form of laser radiation having a wavelength range of between 500 nm and 2200 mm.

30. The method according to claim 29, wherein the wavelength range of the laser radiation is between 700 nm and 1600 nm.

31. The method according to claim 29, wherein the wavelength range of the laser radiation is between 800 nm and 1100 nm.

32. The method according to claim 1, wherein the applying step comprises applying laser power in the range of 10 W to 100 W to target tissue of the patient.

33. The method according to claim 32, wherein the laser power range is between 30 W and 60 W.

34. The method according to claim 1, wherein the applying step comprises applying laser radiation for a period of between 10 minutes and 60 minutes.

35-39. -39. (canceled)

40. A method for treating cancer, comprising the steps of:

applying non-ionizing radiation to a cancer patient; and

administering a non-steroidal anti-androgen to the patient in conjunction with the non-ionizing radiation.

41. The method according to claim 40, wherein the anti-androgen comprises one of bicalutamide and flutamide.

42. The method according to claim 40, wherein the administering step comprises administering the anti-androgen using a dosage in a range of 10 mg/day to 1000 mg/day.

43. The method according to claim 40 wherein the applying step is performed after the administering step.

44. The method according to claim 40, wherein the applying step is performed before the administering step.

45. The method according to claim 40, wherein the applying step is performed simultaneously with the administering step.

46. The method according to claim 40, wherein the patient has prostate cancer, and wherein the applying step comprises applying the radiation to the patient'"'"'s prostate gland.

47. A method for treating cancer, comprising the steps of:

applying non-ionizing radiation to a cancer patient; and

administering an LH-RH agonist to the patient in conjunction with the non-ionizing radiation.

48. The method according to claim 47, wherein the agonist comprises one of leuprorelin acetate, goserelin acetate, buserelin acetate, and tripterelin.

49. The method according to claim 47, wherein the administering step comprises administering the agonist using a dosage in a range of 1 mg/4 weeks to 10 mg/4 weeks.

50. The method according to claim 47, wherein the applying step is performed after the administering step.

51. The method according to claim 47, wherein the applying step is performed before the administering step.

52. The method according to claim 47, wherein the applying step is performed simultaneously with the administering step.

53. The method according to claim 47, wherein the patient has prostate cancer, and wherein the applying step comprises applying the radiation to the patient'"'"'s prostate gland.